Alain Noncovich

Alain Noncovich has extensive experience in synthetic organic and medicinal chemistry. Alain started their career in 2005 as a Postdoctoral Researcher at The Scripps Research Institute, working on studies towards the total synthesis of hyperforin. Alain then joined Senomyx, Inc. in 2006, where they held various positions including Scientist, Senior Scientist, and Principal Scientist. At Senomyx, they were responsible for the discovery and optimization of novel naturally occurring sweet modifiers and TRPM8 active series. Alain also managed scale-up routes for selected product candidates and mentored a team of chemists.

In 2019, Alain Noncovich served as an Adjunct Professor at the Università del Piemonte Orientale, where they conceived and taught a course on Antibody Drug Conjugates (ADCs). Alain later joined Cidara Therapeutics in 2016 as a Senior Scientist, and later became a Senior Scientist II. At Cidara Therapeutics, they worked on the synthesis of improved analogs and designed Antibody Drug Conjugates (ADCs) of the polymixin class.

Most recently, Alain Noncovich has been working at RayzeBio as a Principal Scientist since 2020.

Alain Noncovich's education history begins in 1989 when they attended ITIS "Q. Sella" and obtained a Diploma di Perito Chimico Industriale in Industrial Chemistry in 1994. Alain then pursued further education at Università degli Studi di Torino from 1994 to 2001, earning a Laurea in Chimica (Ms equivalent) with a focus on Organic Chemistry.

In 2002, Alain Noncovich briefly attended Università degli Studi di Torino again and obtained a Licensed Chemist degree in Chemistry. Later, from 2001 to 2004, they attended Università degli Studi del Piemonte Orientale, where they completed a Doctorate in Medicinal and Pharmaceutical Chemistry.

It is worth noting that Alain Noncovich has an additional certification as a Licensed Chemist from Ordine dei Chimici Italiano - Piemonte; however, the specific month and year of obtaining this certification are not provided.